期刊
MOLECULAR ONCOLOGY
卷 1, 期 1, 页码 42-54出版社
WILEY
DOI: 10.1016/j.molonc.2007.01.003
关键词
Antibody; Cancer; CD20; Cytotoxicity; Hybridoma; Therapy
类别
资金
- National Cancer Institute
- Israel Science Foundation
- Israel Cancer Research Fund
- Prostate Cancer Foundation
- German-Israel Foundation
Ten years after the first clinical application of Rituximab, an anti-CD20 recombinant monoclonal antibody, immunotherapy has become common practice in oncology wards. Thanks to the great diversity of the immune system and the powerful methodology of genetic engineering, the pharmacologic potential of antibody-based therapy is far from exhaustion. The recent application of Trastuzumab, an antibody to a receptor tyrosine kinase, in adjuvant breast cancer therapy marks the beginning of a new phase in cancer treatment. Here we discuss molecular mechanisms of antibody-based therapy, the emerging ability to target minimal disease and the therapeutic potential of combining antibodies with other modalities. (C) 2007 Published by Elsevier B.V. on behalf of Federation of European Biochemical Societies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据